Metabolic Diseases
196 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Narrower: Acidosis 12, Adrenal Hyperplasia, Congenital 1, Diabetes Mellitus 95, Diabetes Mellitus, Type 2 72, Diabetic Ketoacidosis 1, Dyslipidemias 29, Glucose Intolerance 2, Glucose Metabolism Disorders 124, Glycogen Storage Disease Type I 1, Hemochromatosis 1, Homozygous Familial Hypercholesterolemia 2, Hypercholesterolemia 7, Hyperglycemia 3, Hyperkalemia 3, Hyperlipidemias 22, Hyperlipoproteinemia Type I 1, Hyperlipoproteinemia Type II 4, Hyperlipoproteinemia Type V 1, Hyperlipoproteinemias 7, Hyperphosphatemia 6, Hypertriglyceridemia 3, Hypoglycemia 5, Hypophosphatasia 1, Insulin Resistance 21, Iron Deficiencies 2, Iron Overload 2, Ketosis 11, Lipid Metabolism Disorders 31, Lysosomal Storage Diseases 1, Metabolic Syndrome 12, Metabolism, Inborn Errors 15, Mitochondrial Diseases 1, Nijmegen Breakage Syndrome 1, Prediabetic State 6, Propionic Acidemia 1, Xanthomatosis 1
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| AI-Guided Multimodal Rehabilitation Program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Alcohol beverage for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aminohippurate Sodium Inj 20% + CANAGLIFLOZIN for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 100 mg TID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 125 mg BID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 125 mg TID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 150 mg BID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 75 mg BID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 75 mg TID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ARBs in combination of SGLT2i for diabetes mellitus | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATR-258 for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + EVOLOCUMAB for hypercholesterolemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + EVOLOCUMAB for hyperlipoproteinemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Avexitide for glucose metabolism disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Avexitide for hypoglycemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| AZD6234 for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Barley beta-glucan(3.0g) for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BBI-001 for hemochromatosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BEAM-301: Single dose of BEAM-301 administered by IV for glycogen storage disease type i | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Berberine ursodeoxycholate for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Berobenatide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Beta glucan for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Body Composition + Blood Draw + CGM/CKM + gradCPT + Ketogenic Diet + Ketone/Glucose Monitoring + NIH Toolbox + PHQ-9 + Resting-state fMRI + SKID + Sleep Monitoring + Task-fMRI + WHO-5 for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for hyperglycemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cagrilintide for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Calorie restricted diet and exercise intervention for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Calorie restriction via total food replacement for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| cfMSC therapy for diabetes for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| cfMSC therapy for diabetes for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CIL001 (Paliroden) for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clazakizumab for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clofutriben for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Continous Glucose Monitor (CGM) + Low-calorie diet + Personalized exercise program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Control for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Control for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CoolSculpting® System for lipid metabolism disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for homozygous familial hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for hyperlipoproteinemia type v | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Culturally Tailored Diabetes Prevention Program for prediabetic state | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Culturally Tailored Diabetes Prevention Program + Culturally Tailored DPP Enhanced with Socioeconomic Supports for prediabetic state | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Danuglipron for diabetes mellitus | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin + Elecoglipron for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin propanediol for iron deficiencies | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| delayed APM group recruit participants with symptoms lasting for more than 6 months for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexcom G6 Professional Continuous Glucose Monitor + INSULIN HUMAN for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexcom G6 Professional Continuous Glucose Monitor + Sliding Scale Insulin for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexcom G6 Professional Continuous Glucose Monitor + Up-Titration of Home Insulin for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Digital Intervention + Metformin for prediabetic state | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| digital prosthetic interface technology for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DMR Procedure for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DMR Procedure (Fractyl) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DR10624 Injection for hypertriglyceridemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Dulaglutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Early arthroscopic partial menisectomy group for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for iron overload | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Efzimfotase Alfa for hypophosphatasia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elecoglipron for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Eloralintide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Eloralintide for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eloralintide + Macupatide for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eloralintide + Tirzepatide for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| eloralintide and tirzepatide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Empagliflozin for ketosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Chloride for hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Decanoate for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Enlicitide Decanoate for hyperlipoproteinemia type ii | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Evolocumab for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Exercise for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exercise for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exploratory test group for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ezetimibe or ezetimibe-statin combination therapy for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ezetimibe or ezetimibe-statin combination therapy for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| fecal microbiota transplantation from healthy lean donors for metabolic syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fixed-Dose Combination Strategy for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fixed-Dose Combination Strategy for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food Security Screening & Referral Program for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food-based diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formula diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green coffee + beta-glucan for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green coffee extract for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GVHD prophylaxis regimen + RIC regimen for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Haploidentical Hematopoietic Cell Transplantation for metabolic diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HD-6277 100mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HD-6277 25mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HD-6277 50mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-dose LC-Z300-01 twice daily in blinding for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity Mediterranean diet intervention for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity Mediterranean diet intervention for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HS-20094 Injection for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hyperpolarized 13C-pyruvate for metabolic syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| icovamenib 100 mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| icovamenib 100mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inclisiran for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Insulin efsitora alfa for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 12 |
| Insulin efsitora alfa for insulin resistance | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensified medical follow-up and glucose-lowering drugs for prediabetic state | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensive lifestyle Intervention for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensive lifestyle Intervention + Meal replacement system for diabetes mellitus, type 2 | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intermittent energy restriction (IER) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intermittent fasting 5:2 + Low-carbohydrate diet + Total diet replacement for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 and K-833 for diabetes mellitus, type 2 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 and K-833 BID + K-757 and K-833 QD for diabetes mellitus, type 2 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Kenetik for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic diet intervention for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laroprovstat for dyslipidemias | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LCHF Ketogenic Diet for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| libitum diet and waiting list control group for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Liraglutide for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-calorie MIND-HK diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-dose LC-Z300-01 twice daily in blinding for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Macupatide for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MAR001 for hypertriglyceridemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Maridebart Cafraglutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Meglumine sodium succinate for diabetic ketoacidosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metreleptin for insulin resistance | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MiniMed 670G system for hypoglycemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MKP10241 for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mRNA-3927 for acidosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mRNA-3927 for propionic acidemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Napazimone for mitochondrial diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Neovasculgen® for diabetes mellitus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| obicetrapib 10 mg + ezetimibe 10 mg FDC daily for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Olezarsen for hyperlipoproteinemia type i | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oral appliance therapy for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Orforglipron for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 15 |
| Osilodrostat for adrenal hyperplasia, congenital | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oxytocin for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment. for metabolic syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Patiromer for hyperkalemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-08653944 for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PG-102 for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Established Dose from prior study, NCT03810196 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine / Topiramate Oral Product for glucose intolerance | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relacorilant for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relacorilant for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for diabetes mellitus | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Retatrutide for insulin resistance | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for metabolic diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RP-A501 for lysosomal storage diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for diabetes mellitus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Semaglutide for glucose intolerance | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for prediabetic state | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Semaglutide + Cagrilintide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Sernova Cell Pouch for hypoglycemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SHR-1918 for homozygous familial hypercholesterolemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium zirconium cyclosilicate for hyperkalemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured weight-loss program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Survodutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Test group for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tifeglipron for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time Restricted Eating (TRE) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time Restricted Eating As Treatment (TREAT) for Diabetes. for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time restricted feeding for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time-restricted eating for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for diabetes mellitus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Tirzepatide for dyslipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for metabolic syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Tirzepatide for prediabetic state | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Topical Simvastatin 2% Cream for xanthomatosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement (800kcal/day) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement (TDR) Program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tranexamic acid for iron deficiencies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treatment with Ketone Supplement for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treatment with Placebo for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treosulfan for nijmegen breakage syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for hypercholesterolemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for hyperlipoproteinemia type ii | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Very Low-calorie MIND-HK diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vicadrostat for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vitamin D supplementation for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VX-017 for hypoglycemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| WS016 for hyperkalemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zenagamtide for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zimislecel for hypoglycemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.